HB2855 EnrolledLRB103 30901 CPF 57441 b HB2855 Enrolled LRB103 30901 CPF 57441 b
HB2855 Enrolled LRB103 30901 CPF 57441 b
1 AN ACT concerning health.
2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
4 Section 5. The Lyme Disease Prevention and Protection Act
5 is amended by changing Section 15 as follows:
6 (410 ILCS 450/15)
7 Sec. 15. Lyme Disease Task Force; duties; members.
8 (a) The Department shall establish the Lyme Disease Task
9 Force to advise the Department on disease prevention and
10 surveillance and provider and public education relating to the
11 disease.
12 (b) The Task Force shall consist of the Director of Public
13 Health or a designee, who shall serve as chairman, and the
14 following members:
15 (1) one representative from the Department of
16 Financial and Professional Regulation, appointed by the
17 Director of Public Health;
18 (2) 3 physicians licensed to practice medicine in all
19 its branches who are members of a statewide organization
20 representing physicians, one of whom represents a medical
21 school faculty and one of whom has the experience of
22 treating Lyme disease, appointed by the Director of Public
23 Health;
HB2855 Enrolled LRB103 30901 CPF 57441 b
HB2855 Enrolled- 2 -LRB103 30901 CPF 57441 b HB2855 Enrolled - 2 - LRB103 30901 CPF 57441 b
HB2855 Enrolled - 2 - LRB103 30901 CPF 57441 b
1 (3) one advanced practice registered nurse selected
2 from the recommendations of professional nursing
3 associations, appointed by the Director of Public Health;
4 (4) one local public health administrator, appointed
5 by the Director of Public Health;
6 (5) one veterinarian, who must be a practicing Doctor
7 of Veterinary Medicine, appointed by the Director of
8 Public Health;
9 (6) one medical entomologist, appointed by the
10 Director of Public Health;
11 (7) (6) 4 members of the public interested in Lyme
12 disease, appointed by the Director of Public Health;
13 (8) (7) 2 members appointed by the Speaker of the
14 House of Representatives;
15 (9) (8) 2 members appointed by the Minority Leader of
16 the House of Representatives;
17 (10) (9) 2 members appointed by the President of the
18 Senate; and
19 (11) (10) 2 members appointed by the Minority Leader
20 of the Senate.
21 (c) The terms of the members of the Task Force shall be 3
22 years. Members may continue to serve after the expiration of a
23 term until a new member is appointed. Each member appointed to
24 fill a vacancy occurring prior to the expiration of the term
25 for which his predecessor was appointed shall be appointed for
26 the remainder of such term. The council shall meet as
HB2855 Enrolled - 2 - LRB103 30901 CPF 57441 b
HB2855 Enrolled- 3 -LRB103 30901 CPF 57441 b HB2855 Enrolled - 3 - LRB103 30901 CPF 57441 b
HB2855 Enrolled - 3 - LRB103 30901 CPF 57441 b
1 frequently as the chairman deems necessary, but not less than
2 4 2 times each year. Members shall receive no compensation for
3 their services.
4 (d) The Lyme Disease Task Force has the following duties
5 and responsibilities:
6 (1) monitoring the implementation of this Act and
7 providing feedback and input for necessary additions or
8 modifications;
9 (2) reviewing relevant literature and guidelines that
10 define accurate diagnosis of Lyme disease with the purpose
11 of creating cohesive and consistent guidelines for the
12 determination of Lyme diagnosis across all counties in
13 Illinois and with the intent of providing accurate and
14 relevant numbers to the Centers for Disease Control and
15 Prevention;
16 (3) providing recommendations on professional
17 continuing educational materials and opportunities that
18 specifically focus on Lyme disease prevention, protection,
19 and treatment; and
20 (4) assisting the Department in establishing policies,
21 procedures, techniques, and criteria for the collection,
22 maintenance, exchange, and sharing of medical information
23 on Lyme disease, and identifying persons or entities with
24 Lyme disease expertise to collaborate with Department in
25 Lyme disease diagnosis, prevention, and treatment.
26 (Source: P.A. 100-1137, eff. 1-1-19; 101-606, eff. 12-13-19.)
HB2855 Enrolled - 3 - LRB103 30901 CPF 57441 b